Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

NCT01495988 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped Slow accrual; toxicity; change in priorities

Conditions

Melanoma
Metastatic Melanoma

Interventions

DRUG: Vemurafenib
DRUG: Bevacizumab
DRUG: Cobimetinib

Sponsor

Melanoma Research Foundation Breakthrough Consortium

Collaborators

[object Object]